Trials / Active Not Recruiting
Active Not RecruitingNCT06731946
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Yibin Fang · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
Detailed description
This study aims to retrospectively evaluate the efficacy and safety of the Surpass Evolve Flow Diverter in treating complex intracranial aneurysms. It seeks to assess long-term outcomes and complication rates while analyzing the impact of patient characteristics and aneurysm types on treatment effectiveness. By collecting data from multiple centers, the study ensures broad representativeness, ultimately providing valuable insights for clinical management on a global scale.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Flow diverting | Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc. |
Timeline
- Start date
- 2024-11-29
- Primary completion
- 2025-10-31
- Completion
- 2025-12-31
- First posted
- 2024-12-13
- Last updated
- 2024-12-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06731946. Inclusion in this directory is not an endorsement.